Mostrar el registro sencillo del ítem

Artículo

dc.creatorPadilla Pérez, María del Carmenes
dc.creatorSánchez Fernández, Elena Matildees
dc.creatorGonzález-Bakker, Adayes
dc.creatorPuerta, Adriánes
dc.creatorPadrón, José M.es
dc.creatorMartín-Loro, Franciscoes
dc.creatorGarcía Fernández, José Manueles
dc.creatorOrtiz Mellet, Carmenes
dc.date.accessioned2023-05-10T08:22:57Z
dc.date.available2023-05-10T08:22:57Z
dc.date.issued2023
dc.identifier.citationPadilla Pérez, M.d.C., Sánchez Fernández, E.M., González-Bakker, A., Puerta, A., Padrón, J.M., Martín-Loro, F.,...,Ortiz Mellet, C. (2023). Fluoro-labelled sp2-iminoglycolipids with immunomodulatory properties. European Journal of Medicinal Chemistry, 255, 115390. https://doi.org/10.1016/j.ejmech.2023.115390.
dc.identifier.issn0223-5234es
dc.identifier.urihttps://hdl.handle.net/11441/145750
dc.description.abstractThe unique electronic properties of the fluorine atom make its strategic incorporation into a bioactive compound a very useful tool in the design of drugs with optimized pharmacological properties. In the field of the carbo- hydrates, its selective installation at C2 position has proven particularly interesting, some 2-deoxy-2-fluorosugar derivatives being currently in the market. We have now transferred this feature into immunoregulatory glyco- lipid mimetics that contain a sp2-iminosugar moiety, namely sp2-iminoglycolipids (sp2-IGLs). The synthesis of two epimeric series of 2-deoxy-2-fluoro-sp2-IGLs, structurally related to nojirimycin and mannonojirimycin, has been accomplished by sequential Selectfluor-mediated fluorination and thioglycosidation of sp2-iminoglycals. Exclusively the α-anomer is obtained regardless of the configurational profile of the sp2-IGL (D-gluco or D-manno), highlighting the overwhelming anomeric effect in these prototypes. Notably, the combination of a fluorine atom at C2 and an α-oriented sulfonyl dodecyl lipid moiety in compound 11 led to remarkable anti-proliferative properties, featuring similar GI50 values than the chemotherapy drug Cisplatin against several tumor cell lines and better selectivity. The biochemical data further evidence a strong reduction of the number of tumor cell colonies and apoptosis induction. Mechanistic investigations revealed that this fluoro-sp2-IGL induces the non- canonical activation mode of the mitogen-activated protein kinase signaling pathway, causing p38α autoacti- vation under an inflammatory context.es
dc.description.sponsorshipVII Plan Propio de Investigación y Transferencia de la Universidad de Sevilla - VIIPPIT-2022-V.1es
dc.description.sponsorshipJunta de Andalucía y Fondos Europeos de Desarrollo Regional -P20_00166es
dc.description.sponsorshipMinisterio de Ciencia e Innovación, Agencia Estatal de Investigación, de España y Fondos Europeos de Desarrollo Regional - PID2019-105858RB-I00, RTI2018-097609-B-C21, PID2021-124247OB-C21 y PID2021-123059OB-I00es
dc.description.sponsorshipInstituto de Salud Carlos III - PI22/01718es
dc.description.sponsorshipConsejería de Universidad, Investigación e Innovación de la Junta de Andalucía - PI20-01331es
dc.description.sponsorshipAgencia Canaria de Investigación Innovación d Sociedad de la Información del Gobierno canario (ACIISI) - TESIS2020010055es
dc.formatapplication/pdfes
dc.format.extent19 p.es
dc.language.isoenges
dc.publisherElsevieres
dc.relation.ispartofEuropean Journal of Medicinal Chemistry, 255, 115390.
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectFluorinated glycomimeticses
dc.subjectSelectfluores
dc.subjectImmunomodulationes
dc.subjectCanceres
dc.subjectInflammationes
dc.subjectp38α MAPKes
dc.titleFluoro-labelled sp2-iminoglycolipids with immunomodulatory propertieses
dc.typeinfo:eu-repo/semantics/articlees
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Química orgánicaes
dc.relation.projectIDPID2019-105858RB-I00es
dc.relation.projectIDRTI2018-097609-B-C21es
dc.relation.projectIDPID2021-124247OB-C21es
dc.relation.projectIDPID2021-123059OB-I00es
dc.relation.projectIDP20_00166es
dc.relation.projectIDPI22/01718es
dc.relation.projectIDPI20-01331es
dc.relation.projectIDACIISI/TESIS2020010055es
dc.relation.projectIDPI20-0036es
dc.relation.publisherversionhttps://doi.org/10.1016/j.ejmech.2023.115390es
dc.identifier.doi10.1016/j.ejmech.2023.115390es
dc.journaltitleEuropean Journal of Medicinal Chemistryes
dc.publication.volumen255es
dc.publication.initialPage115390es
dc.contributor.funderMinisterio de Ciencia e Innovación (MICIN). Españaes
dc.contributor.funderAgencia Estatal de Investigación. Españaes
dc.contributor.funderEuropean Commission (EC). Fondo Europeo de Desarrollo Regional (FEDER)es
dc.contributor.funderUniversidad de Sevillaes
dc.contributor.funderInstituto de Salud Carlos IIIes
dc.contributor.funderJunta de Andalucíaes
dc.contributor.funderGobierno de Canarias. Españaes

FicherosTamañoFormatoVerDescripción
1-s2.0-S0223523423003562-main.pdf5.949MbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Atribución 4.0 Internacional